Pdcd-1L2 Activators
Pdcd-1L2 Activators comprise a range of chemical compounds that indirectly enhance the functional activity of Pdcd-1L2, primarily by modulating immune responses and T cell regulation. BMS-202, a PD-1/PD-L1 interaction inhibitor, plays a critical role in this enhancement. By blocking the PD-1/PD-L1 pathway, which is known for inhibiting T-cell activation, BMS-202 allows for an increased activity of Pdcd-1L2 by reducing competition for PD-1 binding. Similarly, drugs like Cyclophosphamide and Fludarabine, which modulate lymphocyte function, indirectly enhance Pdcd-1L2's role by shifting immune dynamics, thereby reducing lymphocyte-mediated suppression and allowing Pdcd-1L2 pathways to be more prominent. Celecoxib, through its COX-2 inhibition, and Lenalidomide, with its effects on cytokine production, further support the function of Pdcd-1L2 in immune regulation by altering the inflammatory milieu and T cell activation, respectively.
Additionally, compounds like Rapamycin and its analogue Sirolimus, which inhibit mTOR, play a significant role in enhancing Pdcd-1L2 activity. By modulating T cell activation and differentiation, they shift the regulatory balance in favor of pathways where Pdcd-1L2 is involved. Azathioprine and Sunitinib also contribute to this enhancement by suppressing lymphocyte activity and inhibiting tyrosine kinase signaling, respectively, leading to a more pronounced role of Pdcd-1L2 in immune regulation and tumor immunity. Thalidomide's modulation of TNF-α production and Tofacitinib's inhibition of the JAK-STAT pathways further exemplify the diverse mechanisms through which these activators enhance Pdcd-1L2's function in the immune system. Collectively, these Pdcd-1L2 Activators, by targeting various aspects of immune response and signaling pathways, facilitate the enhancement of Pdcd-1L2 mediated functions, particularly in the regulation of T cell responses and immune homeostasis.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cyclophosphamide | 50-18-0 | sc-361165 sc-361165A sc-361165B sc-361165C | 50 mg 100 mg 500 mg 1 g | $90.00 $146.00 $469.00 $791.00 | 18 | |
Cyclophosphamide, an alkylating agent, modulates immune responses. By reducing regulatory T cell activity, it indirectly enhances the functional role of Pdcd-1L2 in immune regulation. This is achieved by shifting the immune balance, allowing for an increased activity of pathways where Pdcd-1L2 is involved, specifically in T cell regulation. | ||||||
Fludarabine | 21679-14-1 | sc-204755 sc-204755A | 5 mg 25 mg | $58.00 $204.00 | 15 | |
Fludarabine, a nucleotide analog, affects lymphocyte function. By decreasing lymphocyte count, it indirectly enhances the activity of Pdcd-1L2. This enhancement occurs as a result of a shift in the immune response dynamics, allowing pathways involving Pdcd-1L2 to become more prominent in the context of reduced lymphocyte-mediated immune suppression. | ||||||
Lenalidomide | 191732-72-6 | sc-218656 sc-218656A sc-218656B | 10 mg 100 mg 1 g | $50.00 $374.00 $2071.00 | 18 | |
Lenalidomide, an immunomodulatory drug, affects cytokine production and T cell activation. By modulating these immune responses, lenalidomide indirectly enhances the activity of Pdcd-1L2 by altering the immune regulatory environment, thereby favoring pathways where Pdcd-1L2 plays a role, especially in T cell regulation and anti-tumor immunity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin, an mTOR inhibitor, influences T cell activation and differentiation. By inhibiting mTOR, it alters T cell responses and indirectly enhances the functional role of Pdcd-1L2 in the immune system. This enhancement is due to the shift in T cell regulatory pathways, where Pdcd-1L2's role is more prominent in the context of mTOR inhibition. | ||||||
Azathioprine | 446-86-6 | sc-210853D sc-210853 sc-210853A sc-210853B sc-210853C | 500 mg 1 g 2 g 5 g 10 g | $203.00 $176.00 $349.00 $505.00 $704.00 | 1 | |
Azathioprine, an immunosuppressive agent, modulates lymphocyte proliferation. By suppressing lymphocyte activity, it indirectly enhances the activity of Pdcd-1L2. This enhancement is a result of the altered balance in immune responses, favoring the pathways in which Pdcd-1L2 is involved, especially in regulating lymphocyte-mediated immune activities. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib, a tyrosine kinase inhibitor, affects various signaling pathways involved in tumor growth and immune responses. By inhibiting these pathways, sunitinib indirectly enhances the functional role of Pdcd-1L2 in immune regulation, particularly in the context of tumor immunity, by shifting the balance towards pathways where Pdcd-1L2 is more active. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $111.00 $357.00 | 8 | |
Thalidomide, an immunomodulatory drug, modulates TNF-α production and immune responses. By altering TNF-α levels and immune cell behavior, thalidomide indirectly enhances the activity of Pdcd-1L2 in immune regulation, particularly in pathways involved in T cell regulation and inflammation. | ||||||
Auranofin | 34031-32-8 | sc-202476 sc-202476A sc-202476B | 25 mg 100 mg 2 g | $153.00 $214.00 $4000.00 | 39 | |
Auranofin, a gold compound, modulates oxidative stress and immune responses. By influencing these processes, it indirectly enhances the activity of Pdcd-1L2, particularly in pathways involved in regulating immune cell function and inflammatory responses. | ||||||